HUAKANG BIOMED (08622): Offeror Receives Valid Acceptance for 96,000 Offer Shares in Total

Stock News

Dec 11, 2025

HUAKANG BIOMED (08622) and the offeror, Anselme Limited, jointly announced that the offer closed at 4:00 p.m. on Thursday, December 11, 2025, without any revision or extension by the offeror. As of 4:00 p.m. on Thursday, December 11, 2025 (the final time and date for accepting the offer as specified in the composite document), the offeror had received valid acceptances for a total of 96,000 offer shares under the share offer, representing approximately 0.02% of the company's total issued share capital as of the date of this joint announcement. No acceptances were received under the warrant offer (with an exercise price of HK$0.125 per share).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1166211437"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1166211437\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1166211437?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166211437","market":"nz","top_or_hot":-1,"title":"HUAKANG BIOMED (08622): Offeror Receives Valid Acceptance for 96,000 Offer Shares in Total","media":"Stock News","content":"<p>HUAKANG BIOMED (08622) and the offeror, Anselme Limited, jointly announced that the offer closed at 4:00 p.m. on Thursday, December 11, 2025, without any revision or extension by the offeror. As of 4:00 p.m. on Thursday, December 11, 2025 (the final time and date for accepting the offer as specified in the composite document), the offeror had received valid acceptances for a total of 96,000 offer shares under the share offer, representing approximately 0.02% of the company's total issued share capital as of the date of this joint announcement. No acceptances were received under the warrant offer (with an exercise price of HK$0.125 per share).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUAKANG BIOMED (08622): Offeror Receives Valid Acceptance for 96,000 Offer Shares in Total</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUAKANG BIOMED (08622): Offeror Receives Valid Acceptance for 96,000 Offer Shares in Total\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-11 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUAKANG BIOMED (08622) and the offeror, Anselme Limited, jointly announced that the offer closed at 4:00 p.m. on Thursday, December 11, 2025, without any revision or extension by the offeror. As of 4:00 p.m. on Thursday, December 11, 2025 (the final time and date for accepting the offer as specified in the composite document), the offeror had received valid acceptances for a total of 96,000 offer shares under the share offer, representing approximately 0.02% of the company's total issued share capital as of the date of this joint announcement. No acceptances were received under the warrant offer (with an exercise price of HK$0.125 per share).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08622","symbol_name":"华康生物医学","start_time":0,"source_url":"","article_id":"1166211437","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166211437","pubTimestamp":1765450963,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUAKANG BIOMED (08622) and the offeror, Anselme Limited, jointly announced that the offer closed at 4:00 p.m. on Thursday, December 11, 2025, without any revision or extension by the offeror. As of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08622":"华康生物医学","BK1222":"医疗保健用品"},"translate_title":"华康生物(08622)：要约人接获合共96,000股发售股份的有效接纳","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08622":1},"content_text":"HUAKANG BIOMED (08622) and the offeror, Anselme Limited, jointly announced that the offer closed at 4:00 p.m. on Thursday, December 11, 2025, without any revision or extension by the offeror. As of 4:00 p.m. on Thursday, December 11, 2025 (the final time and date for accepting the offer as specified in the composite document), the offeror had received valid acceptances for a total of 96,000 offer shares under the share offer, representing approximately 0.02% of the company's total issued share capital as of the date of this joint announcement. No acceptances were received under the warrant offer (with an exercise price of HK$0.125 per share).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}